The Effect of Fc gamma RIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study

Buyukkurt N., ÖZCAN M. A., Ergene U., Payzin B., Tunah S., DEMİRKAN F., ...Daha Fazla

TURKISH JOURNAL OF HEMATOLOGY, cilt.32, sa.2, ss.152-157, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 2
  • Basım Tarihi: 2015
  • Doi Numarası: 10.4274/tjh.2013.0367
  • Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.152-157
  • Anahtar Kelimeler: Fc gamma RIIIA, Diffuse large B-cell lymphoma, Rituximab, ANTI-CD20 MONOCLONAL-ANTIBODY, RITUXIMAB THERAPY, CHOP, EXPRESSION
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective: The curative treatment approach for diffuse large B-cell lymphoma (DLBCL) is controversial even in the rituximab (R) era. The aim of this study was to examine the Fc gamma RIIIA gene polymorphism distribution of DLBCL patients who had been treated with R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Furthermore, we investigated the impact of Fc gamma RIIIA gene polymorphism on the overall response rate (ORR) and overall survival (OS).